Healthcare is messy. If you've ever opened a medical bill and felt your soul leave your body, you know exactly what I’m talking about. It isn’t just the price; it’s the sheer, baffling complexity of the "revenue cycle"—that invisible pipeline where doctors’ notes turn into codes, codes turn into claims, and claims (hopefully) turn into payments.
In June 2024, a company called AKASA quietly secured $120 million to fix this specific nightmare.
Now, $120 million is a lot of money, but in the world of generative AI, it’s almost a baseline. However, this isn't just another Silicon Valley "we added a chatbot to our website" story. This is about the "mid-cycle"—the most profitable and simultaneously broken part of the US healthcare system.
The Reality of AKASA Funding 2024 120 Million
Let’s be real: most people haven't heard of AKASA unless they work in a hospital's back office. They’re a San Francisco-based company founded in 2018 (originally as Alpha Health). They focus on a very niche, very lucrative problem: Revenue Cycle Management (RCM).
When news broke about the AKASA funding 2024 120 million round, it signaled a shift. Investors like Andreessen Horowitz (a16z) and Costanoa Ventures aren't just betting on cool tech; they’re betting on the fact that hospital margins are thinner than ever.
Why is this happening now?
- The Staffing Crisis: Hospitals can’t find enough medical coders. It’s a high-burnout job that requires intense specialization.
- The Denial Problem: Insurance companies are getting better at denying claims. If a code is 1% off, the claim gets kicked back.
- The Complexity of High-Acuity Care: In places like the Cleveland Clinic—one of AKASA’s major partners—the patient cases are incredibly complex. You can't just use a generic AI for that.
AKASA’s whole pitch is that they’ve built a Large Language Model (LLM) that actually understands clinical records. Most AI "reads" text. AKASA claims their system "understands" the nuance of a physician’s note in two seconds.
💡 You might also like: Do You Have to Have Receipts for Tax Deductions: What Most People Get Wrong
The $30 Million Difference
Honestly, the numbers are kind of wild. According to reports following the funding, AKASA’s tech has been shown to decrease accounts receivable days by about 13%. For a massive health system, that’s not just a minor efficiency; it’s millions of dollars in liquidity.
One case study mentioned an 86% improvement in efficiency.
Think about that.
If a human coder takes 20 minutes to process a complex inpatient encounter, and the AI does it in seconds with a "human-in-the-loop" for final verification, the math starts to look very attractive to a CFO.
What most people get wrong about this AI
It’s not replacing humans. Not yet, anyway. The industry calls it "expert-in-the-loop." Basically, the AI does the heavy lifting—reading 100 documents in 90 seconds—and then flags the weird stuff for a human to check.
📖 Related: ¿Quién es el hombre más rico del mundo hoy? Lo que el ranking de Forbes no siempre te cuenta
Is this just more tech hype?
It’s easy to be skeptical. We’ve seen "AI revolutions" in healthcare before that ended up being little more than glorified spreadsheets. But the AKASA funding 2024 120 million is different because of the specific problem it targets: Medical Coding and CDI (Clinical Documentation Integrity).
Medical coding is the bridge between the doctor’s work and the money. If the AI can accurately identify that a patient had three comorbidities instead of one, the hospital gets paid fairly for the actual work performed.
Cleveland Clinic didn't just partner with them for the PR. They’re rolling this out across their entire US enterprise. They deal with some of the highest-acuity (basically, "really sick") patients in the world. If the AI can handle a Cleveland Clinic chart, it can handle anything.
Breaking Down the Investors
The participation of CVS Health Ventures and Kaiser Permanente Ventures in these funding cycles is telling. These aren't just venture capitalists; these are the "incumbents." When the people who pay the bills start investing in the tech that helps hospitals bill them more accurately, you know the tech has moved past the "experimental" phase.
Total funding for AKASA has now climbed over $200 million.
👉 See also: Philippine Peso to USD Explained: Why the Exchange Rate is Acting So Weird Lately
What happens next?
AKASA is using this $120 million to do two things:
- Expand the workforce: They need more engineers and RCM experts.
- R&D for predictive analytics: They want to stop denials before they happen.
The goal is basically a "silent" back office. You go to the doctor, you get treated, the AI handles the paperwork in the background, and the bill you get is actually correct. We’re not there yet, but that’s the $120 million dream.
Actionable Insights for Healthcare Leaders
If you’re sitting in a leadership position at a mid-sized health system, you’ve probably felt the pressure to "do something with AI." Here’s the reality check based on the AKASA trajectory:
- Look at the "Mid-Cycle" first: Don't start with patient-facing chatbots. Start with coding. That’s where the ROI is clearest.
- Data Integrity is everything: AKASA’s AI works because it’s trained on the specific health system’s data. If your data is a mess, the AI will be too.
- Focus on "Superpowers" not replacement: Position AI as a tool to remove the "grunt work" from your staff.
The AKASA funding 2024 120 million news isn't just a business headline. It’s a signal that the administrative side of healthcare is finally getting a serious tech upgrade. It's about time.
Next Steps for Implementation:
- Audit your current "clean claim" rate to identify where the biggest revenue leaks are occurring.
- Evaluate your current RCM staffing levels against your 3-year growth projections to see if automation is a "nice-to-have" or an "imperative."
- Review the specific outcomes of the AKASA-Cleveland Clinic partnership to understand how high-acuity coding can be automated without losing accuracy.